{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:20:13Z","timestamp":1792146013263,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.bbr.2022.113804","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:24:48Z","timestamp":1644971088000},"page":"113804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["The safety and efficacy of ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial"],"prefix":"10.1016","volume":"424","author":[{"given":"Wisam Al","family":"Jumaili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintan","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Kubosumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bbr.2022.113804_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/jcm5110105","article-title":"Posttraumatic stress disorder: overview of evidence-based assessment and treatment","volume":"5","author":"Lancaster","year":"2016","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbr.2022.113804_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-021-01036-x","article-title":"Prevalence of posttraumatic stress disorder after infectious disease pandemics in the twenty-first century, including COVID-19: a meta-analysis and systematic review","author":"Yuan","year":"2021","journal-title":"J. Mol. Psychiatry"},{"key":"10.1016\/j.bbr.2022.113804_bib3","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5\u00ae)","author":"American Psychiatric Association","year":"2013"},{"issue":"2","key":"10.1016\/j.bbr.2022.113804_bib4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.addbeh.2013.08.014","article-title":"Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress","volume":"39","author":"Sofuoglu","year":"2014","journal-title":"Addict. Behav."},{"key":"10.1016\/j.bbr.2022.113804_bib5","article-title":"A review of non anesthetic uses of ketamine","volume":"2020","author":"Pribish","year":"2014","journal-title":"Anesth. Res. Pract."},{"key":"10.1016\/j.bbr.2022.113804_bib6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jss.2020.09.023","article-title":"Post-traumatic stress disorder in adult and pediatric trauma populations: a literature review","volume":"259","author":"Meneses","year":"2021","journal-title":"J. Surg. Res."},{"issue":"6","key":"10.1016\/j.bbr.2022.113804_bib7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.bbr.2022.113804_bib8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.31887\/DCNS.2006.8.4\/jbremner","article-title":"Traumatic stress: effects on the brain","volume":"8","author":"Bremner","year":"2006","journal-title":"Dialog. Clin. Neurosci."},{"issue":"8","key":"10.1016\/j.bbr.2022.113804_bib9","article-title":"Ketamine as treatment for posttraumatic stress disorder: a review","volume":"8","author":"Liriano","year":"2019","journal-title":"Drugs Context."},{"issue":"178","key":"10.1016\/j.bbr.2022.113804_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","article-title":"A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder","volume":"1","author":"Feder","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbr.2022.113804_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cct.2019.04.009","article-title":"Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial","volume":"81","author":"Abdallah","year":"2019","journal-title":"Contemp. Clin Trials"},{"issue":"3","key":"10.1016\/j.bbr.2022.113804_bib12","doi-asserted-by":"crossref","first-page":"17m11634","DOI":"10.4088\/JCP.17m11634","article-title":"Efficacy,\u00a0safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression","volume":"79","author":"Albott","year":"2018","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.bbr.2022.113804_bib13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.bbapap.2018.03.006","article-title":"D-Serine is a potential biomarker for clinical response in treatment of posttraumatic stress disorder using (R, S)-ketamine infusion and TIMBER psychotherapy: a pilot study","volume":"1866","author":"Pradhana","year":"2018","journal-title":"Biochim. Biophys. Acta\u00a0Proteins Proteom."},{"issue":"4","key":"10.1016\/j.bbr.2022.113804_bib14","article-title":"Low dose ketamine infusion for comorbid posttraumatic stress disorder and chronic pain: a randomized double-blind clinical trial","volume":"22","author":"Dadabayev","year":"2020","journal-title":"Chronic Stress"},{"key":"10.1016\/j.bbr.2022.113804_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cct.2019.04.009","article-title":"Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial","volume":"81","author":"Abdallah","year":"2019","journal-title":"Contemp. Clin Trials."},{"issue":"3","key":"10.1016\/j.bbr.2022.113804_bib16","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s00213-005-0094-4","article-title":"Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims","volume":"182","author":"Sch\u00f6nenberg","year":"2005","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.bbr.2022.113804_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000507095","article-title":"Continuous ketamine infusion for pain as an opportunity for psychotherapy for PTSD: a case series of ketamine-enhanced psychotherapy for PTSD and pain (KEP-P2)","volume":"89","author":"Keizer","year":"2020","journal-title":"Psychother. Psychosom."},{"issue":"10","key":"10.1016\/j.bbr.2022.113804_bib18","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/0269881117705089","article-title":"Ketamine\u2019s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders","volume":"31","author":"Glue","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bbr.2022.113804_bib19","article-title":"Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder","volume":"11","author":"Grabski","year":"2022","journal-title":"Am. J. Psychiatry"},{"issue":"11(1)","key":"10.1016\/j.bbr.2022.113804_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41398-021-01327-5","article-title":"Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder","volume":"8","author":"Davis","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbr.2022.113804_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2017.00100","article-title":"The combination of long-term ketamine and extinction training contributes to fear erasure by bdnf methylation","author":"Ju","year":"2017","journal-title":"Front. Cell. Neurosci."},{"issue":"5","key":"10.1016\/j.bbr.2022.113804_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40263-021-00816-x","article-title":"Novel glutamatergic modulators for the treatment of mood disorders: current status","volume":"35","author":"Henter","year":"2021","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.bbr.2022.113804_bib23","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20l13393","article-title":"Does nitrous oxide help veterans with posttraumatic stress disorder? A Case series","volume":"81","author":"Varias","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"281","key":"10.1016\/j.bbr.2022.113804_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jad.2020.12.051","article-title":"The relationship between early administration of morphine or nitrous oxide gas and PTSD symptom development","volume":"15","author":"Deforges","year":"2021","journal-title":"J. Affect. Disorder"},{"issue":"8","key":"10.1016\/j.bbr.2022.113804_bib25","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1017\/S003329171600026X","article-title":"Nitrous oxide speeds the reduction of distressing intrusive memories in an experimental model of psychological trauma","volume":"46","author":"Das","year":"2016","journal-title":"Psychol. Med."},{"issue":"6","key":"10.1016\/j.bbr.2022.113804_bib26","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13233","article-title":"Randomized controlled trial of riluzole augmentation for posttraumatic stress disorder: efficacy of a glutamatergic modulator for antidepressant-resistant symptoms","volume":"81","author":"Spangler","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2022.113804_bib27","unstructured":"Food and drug administration PAXIL (paroxetine hydrochloride) label ,\u00a02012. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020031s067%2C020710s031.pdf\u3009\u00a0(Access 30\u00a0July 2021)."},{"key":"10.1016\/j.bbr.2022.113804_bib28","unstructured":"Food and drug administration ZOLOFT (sertraline hydrochloride) label ,\u00a02016. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019839S74S86S87_20990S35S44S45lbl.pdf\u3009."},{"key":"10.1016\/j.bbr.2022.113804_bib29","unstructured":"Food and drug administration KETALAR (ketamine hydrochloride) label ,\u00a02020. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/016812s046lbl.pdf\u3009 (Access 30\u00a0July 2021)."},{"key":"10.1016\/j.bbr.2022.113804_bib30","unstructured":"Food and drug administration SPRAVATO (esketamine) label, 2019.\u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211243lbl.pdf\u3009\u00a0(Access 30\u00a0July 2021)."},{"issue":"283(14)","key":"10.1016\/j.bbr.2022.113804_bib31","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.283.14.1837","article-title":"Efficacy and safety of sertraline treatment of posttraumatic\u00a0stress disorder: a randomized controlled trial","volume":"12","author":"Brady","year":"2000","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.bbr.2022.113804_bib32","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1176\/appi.ajp.158.12.1982","article-title":"Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study","volume":"158","author":"Marshall","year":"2001","journal-title":"Am. J. Psychiatry"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432822000729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432822000729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:32:00Z","timestamp":1759066320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432822000729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":32,"alternative-id":["S0166432822000729"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2022.113804","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and efficacy of ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2022.113804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113804"}}